Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Exclusion Criteria

• •For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.
• •Known central nervous system involvement.
• •Plasma cell leukemia.
• •History of congestive heart failure.
• •Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.
• •Symptomatic graft versus host disease post allogenic hemopoietic cell transplant within 12 months prior to the first study treatment infusion.
• •Radiotherapy within 21 days prior to the first study treatment infusion.
• •History of any other malignancy known to be active.
• •Known human immunodeficiency virus infection.
• •Patients with active infection requiring systemic anti-infective.
• •Patients with positive test results for hepatitis B surface antigen or Hepatitis B core antigen.
• •Patients with positive test results for hepatitis C virus (HCV) infection.
• •Current active liver or biliary disease.